Indonesia as a malaria endemic country is recommended to use Artemisinin-based Combination Therapy (ACT) for P. vivax malaria. Confirmation of Chloroquine resistant and ACT efficacy for P. vivax need to be investigated for supporting malaria treatment policy. Papua and East Nusa Tenggara (NTT) contribute the main malaria cases in Indonesia. To evaluate efficacy and safety of A…
Drug resistance is one of the global problems, particularly in communicable diseases control including Indonesian malaria elimination program. Since 2004, Artesunate-Amodiaquine (AS+AQ), an Artemisinin based Combination Therapy (ACT), has been used in Indonesia as recommended by the WHO for treatment of acute uncomplicated malaria, replacing of chloroquine resistant antimalarial. Since then, im…
Malaria is still a public health problem in Indonesia. The clinical manifestation of malaria is varied, and many factors may influence its clinical manifestation. Despite the species of malaria, density of parasitemia is known related to the severity or malignancy of malaria. It is worth to analyse the clinical and laboratory data of malaria cases in monitoring dihydroartemisinin-piperaquine (D…
Malaria is still a public health problem in Ogan Komering Ulu (OKU) Regency. The treatment of malaria for Plasmodium falciparum in the OKU regency has been using artesdiaquine since 2007 and for Plasmodium vivax in 2009. The purpose of this study was to assess the effectiveness Artesdiaquine as anti-malarial drugs and the side effects of therapeutic. This research was conducted using an observa…